Next Article in Journal
Insights into Thymus Development and Viral Thymic Infections
Previous Article in Journal
NSs Filament Formation Is Important but Not Sufficient for RVFV Virulence In Vivo
Previous Article in Special Issue
Human Antimicrobial Peptides as Therapeutics for Viral Infections
Open AccessArticle

Brevilin A, a Sesquiterpene Lactone, Inhibits the Replication of Influenza A Virus In Vitro and In Vivo

by 1,*,†, 1,†, 1, 2, 3 and 1,*
1
Department of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, Guangdong, China
2
Institute of Laboratory Animal Science, Jinan University, Guangzhou 510632, Guangdong, China
3
Institute of Traditional Chinese Medicine and Natural Products, Jinan University, Guangzhou 510632, Guangdong, China
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Viruses 2019, 11(9), 835; https://doi.org/10.3390/v11090835
Received: 8 August 2019 / Revised: 4 September 2019 / Accepted: 6 September 2019 / Published: 8 September 2019
(This article belongs to the Special Issue Antiviral Agents)
With the emergence of drug-resistant strains of influenza A viruses (IAV), new antivirals are needed to supplement the existing counter measures against IAV infection. We have previously shown that brevilin A, a sesquiterpene lactone isolated from C. minima, suppresses the infection of influenza A/PR/8/34 (H1N1) in vitro. Here, we further investigate the antiviral activity and mode of action of brevilin A against different IAV subtypes. Brevilin A inhibited the replication of influenza A H1N1, H3N2, and H9N2 viruses in vitro. The suppression effect of brevilin A was observed as early as 4–8 hours post infection (hpi). Furthermore, we determined that brevilin A inhibited viral replication in three aspects, including viral RNA (vRNA) synthesis, expression of viral mRNA, and protein encoded from the M and NS segments, and nuclear export of viral ribonucleoproteins (vRNPs). The anti-IAV activity of brevilin A was further confirmed in mice. A delayed time-to-death with 50% surviving up to 14 days post infection was obtained with brevilin A (at a dose of 25 mg/kg) treated animals compared to the control cohorts. Together, these results are encouraging for the exploration of sesquiterpene lactones with similar structure to brevilin A as potential anti-influenza therapies. View Full-Text
Keywords: influenza A virus; brevilin A; antiviral; sesquiterpene lactone; replication influenza A virus; brevilin A; antiviral; sesquiterpene lactone; replication
Show Figures

Figure 1

MDPI and ACS Style

Zhang, X.; Xia, Y.; Yang, L.; He, J.; Li, Y.; Xia, C. Brevilin A, a Sesquiterpene Lactone, Inhibits the Replication of Influenza A Virus In Vitro and In Vivo. Viruses 2019, 11, 835.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop